Results 31 to 40 of about 178,566 (304)
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Prospecting the protein design landscape
FEBS Letters, EarlyView.This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona +4 more
wiley +1 more source
Sensor-Independent LAI/FPAR CDR
, 2023 The Sensor-Independent leaf area index (LAI)/ fraction of photosynthetically active radiation (FPAR) climate data record (CDR) is derived from high quality LAI/FPAR from MOD15AH C6, MYD15A2H C6, and VNP15A2H C1 products.
Roy, Samapriya +3 more
core +1 more source
Smaller is better: nanobodies meet NMR
FEBS Letters, EarlyView.Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley +1 more source
Participants’ average age, education, and gender classified by CDR & CDR-SOB stage (M±SD).
, 2016 Participants’ average age, education, and gender classified by CDR & CDR-SOB stage (M±SD).
Young Ho Park (431181) +3 more
core +1 more source
Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy
FEBS Letters, EarlyView.The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley +1 more source
Neuroimaging and clinical characteristics of cognitive migration in community-dwelling older adults
NeuroImage: Clinical, 2022 Background: Multiple neuroimaging and clinical biomarkers have been identified to predict cognitive decline and clinical progression to mild cognitive impairment (MCI) or dementia.
Tugce Duran +8 more
doaj +1 more source
Molecular Oncology, EarlyView.LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
, 2003 Meyer Institute Guest Speaker Presentation, arranged by Professor William SolitarioJuly 17, 2003, CDR Glaros, OSD, Force ...
Glaros, CDR
core +1 more source
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Diabetes‐associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking ...
Osman Corbali +4 more
wiley +1 more source